Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $126.3 million.

  • Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) rose 3.71% to $126.3 million in Q3 2025 from the same period last year, while for Jun 2025 it was $125.7 million, marking a year-over-year increase of 3.56%. This contributed to the annual value of $124.4 million for FY2024, which is 4.97% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $126.3 million, which was up 0.48% from $125.7 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $126.3 million during Q3 2025, and its lowest value of $80.4 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $120.9 million, with a median of $121.4 million in 2024.
  • Data for Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 32.33% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $87.3 million in 2021, then rose by 26.67% to $110.6 million in 2022, then grew by 7.17% to $118.5 million in 2023, then rose by 4.97% to $124.4 million in 2024, then grew by 3.71% to $126.3 million in 2025.
  • Its last three reported values are $126.3 million in Q3 2025, $125.7 million for Q2 2025, and $125.5 million during Q1 2025.